XOMA Royalty Corporation Announces Cash Dividends for Series A and Series B Preferred Stock

XOMA Royalty Corporation announces upcoming cash dividends for Series A and B Preferred Stock, payable January 15, 2025.

Quiver AI Summary

XOMA Royalty Corporation has announced that its Board of Directors has authorized cash dividends for holders of its Series A and Series B Cumulative Preferred Stock, payable on or about January 15, 2025. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive $0.53906 per share, while holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. The record date for these dividends will be January 3, 2025. XOMA Royalty is a biotechnology royalty aggregator focused on enhancing human health by acquiring future economic rights from therapeutic candidates licensed to pharmaceutical companies, providing sellers with non-dilutive funding for their projects.

Potential Positives

• The announcement of cash dividends reflects the company's commitment to returning value to its preferred shareholders.
• Establishing a payment date and record date provides transparency and clarity for investors regarding the dividend process.
• The press release highlights a diverse and growing portfolio of assets, which may indicate potential future revenue streams for the company.

Potential Negatives

• The announcement of cash dividends may indicate limited cash flow or profitability, which could raise concerns among investors about the company's financial health.
• The press release highlights that all other assets in the royalties and milestone portfolio are investigational compounds, emphasizing the uncertainty and risks involved, as there is no guarantee these will lead to commercial products.
• The statement that "efficacy and safety have not been established" for investigational compounds can lead to apprehension regarding the potential success and future revenue of the company's portfolio.

FAQ

What are the cash dividends announced by XOMA Royalty Corporation?

XOMA announced cash dividends of $0.53906 for Series A and $0.52344 for Series B preferred stockholders.

When will the cash dividends be paid to shareholders?

The dividends will be paid on or about January 15, 2025, to holders of record at the close of business on January 3, 2025.

What types of preferred stock does XOMA Royalty have?

XOMA Royalty has Series A Cumulative Perpetual Preferred Stock and Series B Cumulative Perpetual Preferred Stock.

What does XOMA Royalty Corporation do?

XOMA Royalty aggregates biotechnology royalties and provides funding for biotech companies to advance their therapeutic candidates.

How can I find more information about XOMA Royalty?

More information can be found on XOMA's website at www.xoma.com or on their LinkedIn page.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$XOMA Insider Trading Activity

$XOMA insiders have traded $XOMA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $XOMA stock by insiders over the last 6 months:

• THOMAS M. BURNS (SVP, Finance & CFO) sold 9,775 shares.
• OWEN HUGHES (Chief Executive Officer) sold 21,881 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$XOMA Hedge Fund Activity

We have seen 30 institutional investors add shares of $XOMA stock to their portfolio, and 22 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• STONEPINE CAPITAL MANAGEMENT, LLC removed 55,033 shares (-22.0%) from their portfolio in Q3 2024
• FMR LLC removed 51,003 shares (-4.4%) from their portfolio in Q3 2024
• ACUITAS INVESTMENTS, LLC removed 35,139 shares (-28.5%) from their portfolio in Q3 2024
• BLACKROCK, INC. added 23,173 shares (+4.5%) to their portfolio in Q3 2024
• WOODLINE PARTNERS LP added 23,128 shares (+32.0%) to their portfolio in Q3 2024
• ELLSWORTH ADVISORS, LLC added 19,475 shares (+inf%) to their portfolio in Q3 2024
• MORGAN STANLEY added 15,736 shares (+9.4%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:

Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.

The preferred dividends will be paid on or about January 15, 2025, to respective holders of record at the close of business on January 3, 2025.

About XOMA Royalty Corporation



XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about XOMA Royalty and its portfolio, please visit

www.xoma.com

or follow the Company on

LinkedIn

.

As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet).  All other assets in the milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.